<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112879</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-IRB-7469</org_study_id>
    <secondary_id>CDR0000428248</secondary_id>
    <secondary_id>CCF-IRB-5241</secondary_id>
    <secondary_id>CCF-CTI-T12016</secondary_id>
    <nct_id>NCT00112879</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Thalidomide may stop the growth of multiple myeloma by blocking blood&#xD;
      flow to the cancer. Giving arsenic trioxide together with ascorbic acid, dexamethasone, and&#xD;
      thalidomide may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with&#xD;
      ascorbic acid, dexamethasone, and thalidomide work in treating patients with multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with previously untreated high-risk or relapsed&#xD;
           or refractory multiple myeloma (MM) treated with arsenic trioxide, ascorbic acid,&#xD;
           dexamethasone, and thalidomide.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of response, progression-free survival, and overall survival of&#xD;
           patients with previously untreated high-risk MM treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
        -  Induction therapy: Patients receive arsenic trioxide IV over 1-4 hours and ascorbic acid&#xD;
           IV over 15-30 minutes on days 1-5 in week 1 and then twice weekly in weeks 2-12; oral&#xD;
           dexamethasone on days 1-4, 11-14, 29-32, 39-42, 57-60, and 67-70 (weeks 1, 2, 5, 6, 9,&#xD;
           and 10); and oral thalidomide once daily in weeks 1-12.&#xD;
&#xD;
        -  Consolidation therapy: Beginning 4 weeks after completion of induction therapy, patients&#xD;
           receive arsenic trioxide and ascorbic acid as in induction therapy; oral dexamethasone&#xD;
           on days 1-4, 29-32, and 57-60 (weeks 1, 5, and 9); and oral thalidomide once daily in&#xD;
           weeks 1-12.&#xD;
&#xD;
        -  Maintenance therapy: Beginning 4 weeks after completion of consolidation therapy,&#xD;
           patients receive arsenic trioxide IV over 1-4 hours and ascorbic acid IV over 15-30&#xD;
           minutes on days 1, 8, 15, and 22. Treatment with arsenic trioxide and ascorbic acid&#xD;
           repeats every 90 days (every 12 weeks). Patients also receive oral dexamethasone on days&#xD;
           1-4. Treatment with dexamethasone repeats every 28 days. Patients receive oral&#xD;
           thalidomide once daily. Maintenance therapy continues in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33-68 patients (15-34 with previously untreated high-risk&#xD;
      multiple myeloma [MM] and 18-34 with relapsed or refractory MM) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>Refractory Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiangiogenesis therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>drug resistance inhibition</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>growth factor antagonist therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-specific immune-modulator therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma (MM), meeting 1 of the following criteria:&#xD;
&#xD;
          -  Previously untreated disease with poor prognosis, meeting 1 of the following criteria:&#xD;
&#xD;
          -  Active disease with β2 microglobulin ≥ 5.5 mg/dL&#xD;
&#xD;
          -  Inactive disease with peripheral plasma cells OR chromosome 13 or 14 abnormalities by&#xD;
             fluorescent in situ hybridization&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Measurable disease by serum and urine M-protein and/or measurable plasmacytoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2* NOTE: *ECOG 3 allowed for patients with bone pain due to MM&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3 unless plasma cells &gt; 50% in bone marrow&#xD;
&#xD;
          -  Any WBC allowed provided plasma cells &gt; 50% in bone marrow&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 6.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Absolute QT interval ≤ 460 msec with potassium ≥ 4.0 mEq/L AND magnesium ≥ 1.8 mg/dL&#xD;
&#xD;
          -  No conduction defects&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No other significant underlying cardiac dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception for ≥ 4 weeks before,&#xD;
             during, and for ≥ 4 weeks after completion of study therapy&#xD;
&#xD;
          -  No blood, ova, or sperm donation during study participation&#xD;
&#xD;
          -  No history of grand mal seizures except infantile febrile seizures&#xD;
&#xD;
          -  No pre-existing neurotoxicity or neuropathy ≥ grade 2&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No active serious infection that cannot be controlled with antibiotics&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No other condition that would preclude study compliance or follow up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior thalidomide allowed (in patients with relapsed or refractory MM)&#xD;
&#xD;
          -  No prior thalidomide in combination with arsenic trioxide&#xD;
&#xD;
          -  Prior epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  Prior arsenic trioxide allowed (for patients with relapsed or refractory MM)&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
          -  No chemotherapy within 2 weeks after completion of study treatment&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior steroid therapy allowed (for patients with relapsed or refractory MM)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent broad-field radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior and concurrent bisphosphonates allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad A. Hussein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

